Abstract
MicroAbstract New treatment agents have not shown sufficient efficacy against advanced squamous cell lung cancer. In the present phase II study, the primary endpoint was the objective response rate, and the combination of nedaplatin and paclitaxel appeared safe and effective for untreated advanced squamous cell lung cancer. The objective response rate was 72.2%, and the disease control rate was 100%.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
